Targeting apoptosis in cancer therapy

[1]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[2]  Ayrianne J. Crawford,et al.  CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax , 2019, Molecular Pharmacology.

[3]  G. Grech,et al.  Loss of MCL1 function sensitizes the MDA‐MB‐231 breast cancer cells to rh‐TRAIL by increasing DR4 levels , 2019, Journal of cellular physiology.

[4]  Case Report Abstract , 2019, European Heart Journal Supplements.

[5]  E. Thompson,et al.  Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma , 2019, British journal of haematology.

[6]  A. Kater,et al.  Ibrutinib and Venetoclax for First-Line Treatment of CLL. , 2019, The New England journal of medicine.

[7]  J. Byrd,et al.  Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. , 2019, Blood.

[8]  E. Rasmussen,et al.  Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. , 2019, Blood advances.

[9]  F. Colland,et al.  Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models , 2019, Experimental and Molecular Therapeutics.

[10]  F. Colland,et al.  Abstract 4477: MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies , 2019, Experimental and Molecular Therapeutics.

[11]  E. Tam,et al.  Abstract 2491: Engineering and preclinical activity of MM-201, a best-in-class TRAIL receptor agonist , 2019, Molecular and Cellular Biology / Genetics.

[12]  Dajun Yang,et al.  Abstract 2058: BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma , 2019, Experimental and Molecular Therapeutics.

[13]  Hong Wang,et al.  Abstract 3: Discovery and optimization of small molecule Bax activators for cancer therapy , 2019, Cancer Chemistry.

[14]  P. Parren,et al.  Abstract 2391: DR5 agonist activity of HexaBody®-DR5/DR5 (GEN1029) is potentiated by C1q and independent of Fc-gamma receptor binding in preclinical tumor models , 2019, Immunology.

[15]  W. El-Deiry,et al.  Abstract 258: Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic , 2019, Experimental and Molecular Therapeutics.

[16]  W. El-Deiry,et al.  Abstract 262: Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro , 2019, Experimental and Molecular Therapeutics.

[17]  L. Skalniak,et al.  Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists , 2019, Cancers.

[18]  T. Sakellaropoulos,et al.  Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. , 2019, Cancer discovery.

[19]  G. Morin,et al.  The interaction between SPARC and GRP78 interferes with ER stress signaling and potentiates apoptosis via PERK/eIF2α and IRE1α/XBP-1 in colorectal cancer , 2019, Cell Death & Disease.

[20]  D. Baker,et al.  Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity , 2019, Science Immunology.

[21]  R. Sciot,et al.  Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification , 2019, Clinical and Translational Oncology.

[22]  T. Vanden Berghe,et al.  Targeting Ferroptosis to Iron Out Cancer. , 2019, Cancer cell.

[23]  T. Kipps,et al.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. , 2019, The New England journal of medicine.

[24]  P. Colman,et al.  Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations , 2019, Nature Communications.

[25]  D. Green,et al.  Autophagy-Independent Functions of the Autophagy Machinery , 2019, Cell.

[26]  Naveen Garg,et al.  Ibrutinib and Venetoclax for First-Line Treatment of CLL. , 2019, The New England journal of medicine.

[27]  J. Desai,et al.  Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. , 2019, Journal of Clinical Oncology.

[28]  Z. Ignatova,et al.  ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumor progression , 2019, Nature Cell Biology.

[29]  S. Libutti,et al.  Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration , 2019, Journal of Immunotherapy for Cancer.

[30]  M. Mehta,et al.  Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. , 2019, Journal of Clinical Oncology.

[31]  K. Gelmon,et al.  A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. , 2019, Journal of Clinical Oncology.

[32]  M. Ratain,et al.  Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. , 2019, Journal of Clinical Oncology.

[33]  D. Krysko,et al.  Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion , 2019, Nature Reviews Cancer.

[34]  D. Green.  The Coming Decade of Cell Death Research: Five Riddles , 2019, Cell.

[35]  Kaiwen W. Chen,et al.  Extrinsic and intrinsic apoptosis activate pannexin‐1 to drive NLRP3 inflammasome assembly , 2019, The EMBO journal.

[36]  S. McWeeney,et al.  The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. , 2019, Cancer discovery.

[37]  G. Salles,et al.  Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. , 2019, Blood.

[38]  Andrew B. Leber,et al.  Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. , 2019, Cancer cell.

[39]  Erguang Li,et al.  Palbociclib triggers apoptosis in bladder cancer cells by Cdk2‐induced Rad9‐mediated reorganization of the Bak.Bcl‐xl complex , 2019, Biochemical pharmacology.

[40]  Laura E. Herring,et al.  Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues , 2019, ACS chemical biology.

[41]  Tianyu Li,et al.  LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma , 2019, Molecular Cancer Therapeutics.

[42]  Y. Lim,et al.  Salinomycin-Loaded Gold Nanoparticles for Treating Cancer Stem Cells by Ferroptosis-Induced Cell Death. , 2019, Molecular pharmaceutics.

[43]  E. Froňková,et al.  Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma , 2019, Clinical Cancer Research.

[44]  E. Alnemri,et al.  Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation , 2019, Nature Communications.

[45]  M. Mehta,et al.  First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. , 2019, Journal of neurosurgery. Pediatrics.

[46]  J. Staerk,et al.  The kinase PERK and the transcription factor ATF4 play distinct and essential roles in autophagy resulting from tunicamycin-induced ER stress , 2019, The Journal of Biological Chemistry.

[47]  Robert M. Vogel,et al.  Mitochondrial origins of fractional control in regulated cell death , 2019, Nature Communications.

[48]  A. Wei,et al.  Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Ami A. Shah,et al.  Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma , 2019, Nature Communications.

[50]  Shaji K. Kumar,et al.  Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma , 2019, Haematologica.

[51]  A. Levine.  Targeting Therapies for the p53 Protein in Cancer Treatments , 2019, Annual Review of Cancer Biology.

[52]  A. Dömling,et al.  Stapled Peptides Inhibitors: A New Window for Target Drug Discovery , 2019, Computational and structural biotechnology journal.

[53]  B. Durden,et al.  ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining “stemness” , 2019, Cell Death & Disease.

[54]  A. Tolcher,et al.  A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. , 2019 .

[55]  G. Mills,et al.  Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness , 2019, Molecular Cancer Therapeutics.

[56]  A. Letai,et al.  Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins , 2019, Nature Reviews Molecular Cell Biology.

[57]  K. Rajapakshe,et al.  Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells , 2019, Blood Cancer Journal.

[58]  Thomas M. Harris,et al.  Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1 , 2019, Oncotarget.

[59]  J. Wan,et al.  MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells , 2019, Leukemia & lymphoma.

[60]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[61]  R. Kitsis,et al.  Small Molecule Allosteric Inhibitors of BAX , 2018, Nature Chemical Biology.

[62]  E. Thompson,et al.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. , 2018, Cancer discovery.

[63]  Myung Ah Lee,et al.  Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[64]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[65]  V. Costa,et al.  The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.

[66]  J. Toldrà,et al.  American Association for Cancer Research (AACR) - 110th Annual Meeting. Atlanta, Georgia, USA - March 29-April 3, 2019 , 2019, Drugs of the future.

[67]  Jessica M. Rusert,et al.  Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism , 2018, Clinical Cancer Research.

[68]  J. A. Hendricks,et al.  Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia , 2018, Nature Communications.

[69]  A. Giobbie-Hurder,et al.  Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma , 2018, Melanoma research.

[70]  R. Korn,et al.  Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma , 2018, Blood.

[71]  J. Keats,et al.  Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma , 2018, Blood.

[72]  S. Dawson,et al.  Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma , 2018, Nature Medicine.

[73]  V. Seshan,et al.  NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death , 2018, Proceedings of the National Academy of Sciences.

[74]  Guochao Liao,et al.  The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy. , 2018, European journal of medicinal chemistry.

[75]  D. Green,et al.  Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection , 2018, Proceedings of the National Academy of Sciences.

[76]  A. Roberts,et al.  Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Bertin,et al.  Pathogen blockade of TAK1 triggers caspase-8–dependent cleavage of gasdermin D and cell death , 2018, Science.

[78]  L. Skalniak,et al.  Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells , 2018, Cancers.

[79]  G. Vuagniaux,et al.  SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer , 2018, Clinical Cancer Research.

[80]  A. Drilon,et al.  NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.

[81]  Sean P. Brown,et al.  Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer. , 2018, Cancer discovery.

[82]  Sean P. Brown,et al.  AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. , 2018, Cancer discovery.

[83]  Sung-Bae Kim,et al.  Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  F. Colland,et al.  Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia , 2018, Leukemia.

[85]  E. Olejniczak,et al.  A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. , 2018, Cancer discovery.

[86]  K. Stegmaier,et al.  Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. , 2018, Cell reports.

[87]  J. Blay,et al.  Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma , 2018, Oncogenesis.

[88]  Yan Li,et al.  MEK inhibitors induce apoptosis via FoxO3a-dependent PUMA induction in colorectal cancer cells , 2018, Oncogenesis.

[89]  Lorin Crawford,et al.  Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity , 2018, Nature Communications.

[90]  A. Look,et al.  The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells , 2018, Leukemia.

[91]  J. Leeds,et al.  Abstract 305: Cerdulatinib induces Bim expression and synergistic cell kill in combination with venetoclax in follicular lymphoma cell lines , 2018, Molecular and Cellular Biology / Genetics.

[92]  A. Graber,et al.  Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients withTP53mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) , 2018, Clinical Trials.

[93]  Y. Zeng,et al.  BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc , 2018, Cell Death & Disease.

[94]  Liqing Zhou,et al.  Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib , 2018, Clinical lung cancer.

[95]  F. Mirza,et al.  BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition , 2018, Oncotarget.

[96]  T. Vanden Berghe,et al.  Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma , 2018, The Journal of clinical investigation.

[97]  M. Taniwaki,et al.  Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2 , 2018, Investigational New Drugs.

[98]  S. Fulda,et al.  BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis , 2018, Oncogene.

[99]  W. El-Deiry,et al.  Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment , 2018, The Journal of clinical investigation.

[100]  H. Düssmann,et al.  BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucose , 2018, Oncotarget.

[101]  Joshua M. Dempster,et al.  Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models , 2018, Nature Communications.

[102]  A. Tolcher,et al.  A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. , 2018 .

[103]  T. Graeber,et al.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.

[104]  G. Gordon,et al.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  G. Cohen,et al.  S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth , 2018, Oncotarget.

[106]  A. Verma,et al.  Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia , 2018, Science Translational Medicine.

[107]  S. Lade,et al.  Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma , 2018, The New England journal of medicine.

[108]  D. Lee,et al.  Ferroptosis-Induced Endoplasmic Reticulum Stress: Cross-talk between Ferroptosis and Apoptosis , 2018, Molecular Cancer Research.

[109]  Marco Montillo,et al.  Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.

[110]  T. Habermann,et al.  A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers , 2018, The oncologist.

[111]  K. Rogers,et al.  BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis , 2018, Science.

[112]  Viktor Achter,et al.  Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia , 2018, Nature Communications.

[113]  H. Rupasinghe,et al.  Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.

[114]  G. Blandino,et al.  New therapeutic strategies to treat human cancers expressing mutant p53 proteins , 2018, Journal of Experimental & Clinical Cancer Research.

[115]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[116]  J. Zhi,et al.  Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML , 2018, Cancer Chemotherapy and Pharmacology.

[117]  S. Dixon,et al.  p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells. , 2018, Cell reports.

[118]  A. Keating,et al.  Iterative optimization yields Mcl-1–targeting stapled peptides with selective cytotoxicity to Mcl-1–dependent cancer cells , 2018, Proceedings of the National Academy of Sciences.

[119]  H. Seo,et al.  Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor. , 2018, Structure.

[120]  D. Green,et al.  MOMP, cell suicide as a BCL-2 family business. , 2018 .

[121]  J. Schulte,et al.  Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma , 2017, Oncotarget.

[122]  K. Wiman,et al.  Targeting mutant p53 for efficient cancer therapy , 2017, Nature Reviews Cancer.

[123]  W. El-Deiry,et al.  Role of Dopamine Receptors in the Anticancer Activity of ONC20112 , 2017, Neoplasia.

[124]  Y. Pekarsky,et al.  BCL2 and miR-15/16: from gene discovery to treatment , 2017, Cell Death and Differentiation.

[125]  E. Novellino,et al.  Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells. , 2017, ACS chemical neuroscience.

[126]  S. Fulda,et al.  BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. , 2018, Cancer letters.

[127]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[128]  H. Düssmann,et al.  Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells , 2018, Cell Death & Disease.

[129]  Yan Zhou,et al.  miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells. , 2017, Cancer research.

[130]  S. Morgan-Lappe,et al.  Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors , 2017 .

[131]  A. Letai,et al.  Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. , 2017, Cancer discovery.

[132]  J. Yu,et al.  Cysteine Dioxygenase 1 Mediates Erastin-Induced Ferroptosis in Human Gastric Cancer Cells1 , 2017, Neoplasia.

[133]  K. Wiman,et al.  APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 , 2017, Cell Death & Disease.

[134]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[135]  A. Verma,et al.  Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. , 2017, Cancer cell.

[136]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[137]  A. Oberst,et al.  Mitochondrial permeabilisation engages NF-κB dependent anti-tumour activity under caspase deficiency , 2017, Nature Cell Biology.

[138]  Julia N. Soulakova,et al.  Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells , 2017, Molecular Cancer Therapeutics.

[139]  Liang Deng,et al.  Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation , 2017, Clinical Cancer Research.

[140]  Xiaozhen Liu,et al.  Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion‐positive non–small cell lung cancer , 2017, Cancer.

[141]  A. Thorburn,et al.  Targeting autophagy in cancer , 2017, Nature Reviews Cancer.

[142]  A. Ullrich,et al.  GAS6‐expressing and self‐sustaining cancer cells in 3D spheroids activate the PDK‐RSK‐mTOR pathway for survival and drug resistance , 2017, Molecular oncology.

[143]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[144]  S. Morgan-Lappe.  Abstract DDT01-03: ABBV-621: A best-in-class TRAIL-receptor agonist fusion protein that enhances optimal clustering for the treatment of solid and hematologic tumors , 2017 .

[145]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[146]  E. Petricoin,et al.  Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. , 2017, Blood advances.

[147]  G. Salles,et al.  A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY , 2017 .

[148]  W. Curran,et al.  Modulation of Bax and mTOR for Cancer Therapeutics. , 2017, Cancer research.

[149]  R. Amaravadi,et al.  Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors , 2017, International journal of molecular sciences.

[150]  W. El-Deiry,et al.  The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia , 2017, Cell cycle.

[151]  K. Flaherty,et al.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. , 2017, Cancer research.

[152]  S. Gore,et al.  Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings , 2017, Leukemia & lymphoma.

[153]  J. Schellens,et al.  A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. , 2017, European journal of cancer.

[154]  Chao-Yie Yang,et al.  Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. , 2017, Cold Spring Harbor perspectives in medicine.

[155]  Liu Liu,et al.  Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development , 2017, Journal of medicinal chemistry.

[156]  A. Chakravarthy,et al.  The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 , 2017, Molecular cell.

[157]  Juan R. Cubillos-Ruiz,et al.  Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer , 2017, Cell.

[158]  S. Nagata,et al.  Programmed cell death and the immune system , 2017, Nature Reviews Immunology.

[159]  M. Konopleva,et al.  Pathways and mechanisms of venetoclax resistance , 2017, Leukemia & lymphoma.

[160]  A. Letai,et al.  Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. , 2017, Cancer cell.

[161]  A. Letai,et al.  Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors , 2017, FEBS letters.

[162]  A. Italiano,et al.  MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas , 2017, Oncotarget.

[163]  M. Amiot,et al.  Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. , 2016, Blood.

[164]  A. Fattaey,et al.  The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL , 2016 .

[165]  Y. Asmann,et al.  IAP antagonists induce anti-tumor immunity in multiple myeloma , 2016, Nature Medicine.

[166]  M. Prados,et al.  Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. , 2016, Neuro-oncology.

[167]  A. Strasser,et al.  The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models , 2016, Nature.

[168]  Philipp Holzer,et al.  Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. , 2016, Bioorganic & medicinal chemistry letters.

[169]  Joon Sang Lee,et al.  TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma , 2016, Nature Communications.

[170]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[171]  M. Gonen,et al.  Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth , 2016, Nature nanotechnology.

[172]  Michel Theron,et al.  Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts , 2016, Haematologica.

[173]  A. Richardson,et al.  Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells , 2016, Journal of Ovarian Research.

[174]  A. Tolcher,et al.  A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors , 2016, Clinical Cancer Research.

[175]  T. Ciuleanu,et al.  A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[176]  B. Stockwell,et al.  Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis , 2016, Nature chemical biology.

[177]  Michael L. Wang,et al.  ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies , 2016, Science Signaling.

[178]  W. El-Deiry,et al.  ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases , 2016, Science Signaling.

[179]  E. Kohn,et al.  Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or ‐refractory epithelial ovarian cancer , 2016, Cancer.

[180]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[181]  W. El-Deiry,et al.  The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death* , 2016, The Journal of Biological Chemistry.

[182]  Ping Wang,et al.  Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo , 2016, Clinical Cancer Research.

[183]  P. Parren,et al.  A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface , 2016, PLoS biology.

[184]  Jian Yu,et al.  mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction upon 4E-BP1 dephosphorylation , 2015, Oncogene.

[185]  W. Janzen,et al.  High Throughput Screening , 2016, Methods in Molecular Biology.

[186]  L. Del Valle,et al.  Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. , 2015, Blood.

[187]  D. Green,et al.  Cell Death Signaling. , 2015, Cold Spring Harbor perspectives in biology.

[188]  Gloria S. Huang,et al.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. , 2015, Seminars in cancer biology.

[189]  J. Nemunaitis,et al.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer , 2015, Science Translational Medicine.

[190]  S. Fulda.  Promises and Challenges of Smac Mimetics as Cancer Therapeutics , 2015, Clinical Cancer Research.

[191]  P. Vyas,et al.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia , 2015, Clinical Cancer Research.

[192]  A. Cleton-Jansen,et al.  Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin , 2015, Oncotarget.

[193]  J. Thomas,et al.  Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma , 2015, Annals of surgical oncology.

[194]  A. Adjei,et al.  A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma , 2015, Molecular Cancer Therapeutics.

[195]  D. Andrews,et al.  Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. , 2015, The Biochemical journal.

[196]  D. Planchard,et al.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[197]  J. Werner,et al.  Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. , 2015, Cancer cell.

[198]  N. Tsomaia.  Peptide therapeutics: targeting the undruggable space. , 2015, European journal of medicinal chemistry.

[199]  W. Gu,et al.  Ferroptosis as a p53-mediated activity during tumour suppression , 2015, Nature.

[200]  I. Flinn,et al.  Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. , 2015, The Lancet. Haematology.

[201]  W. El-Deiry,et al.  Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. , 2015, Cancer research.

[202]  T. Kipps,et al.  A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia , 2015, Leukemia & lymphoma.

[203]  Dolores Diaz,et al.  Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy , 2015, Science Translational Medicine.

[204]  R. Deberardinis,et al.  Metabolic pathways promoting cancer cell survival and growth , 2015, Nature Cell Biology.

[205]  R. Myers,et al.  TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer , 2015, Clinical Cancer Research.

[206]  T. Meitinger,et al.  CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. , 2015, American journal of human genetics.

[207]  B. Chauffert,et al.  The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. , 2015, Cancer letters.

[208]  D. Newmeyer,et al.  Mitochondrial shape governs BAX-induced membrane permeabilization and apoptosis. , 2015, Molecular cell.

[209]  James M. Bogenberger,et al.  Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies , 2015, Leukemia & lymphoma.

[210]  C. Tse,et al.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) , 2015, Cell Death and Disease.

[211]  Russell S. Peak,et al.  Part 2: , 2020, Journal of Neural Transmission.

[212]  Jian Sun,et al.  The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells , 2015, Tumor Biology.

[213]  T. Taniguchi,et al.  Apoptotic Caspases Prevent the Induction of Type I Interferons by Mitochondrial DNA , 2014, Cell.

[214]  Matthew E. Ritchie,et al.  Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production , 2014, Cell.

[215]  Francoise Powell,et al.  A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model , 2014 .

[216]  G. Jeschke,et al.  Structural model of active Bax at the membrane. , 2014, Molecular cell.

[217]  B. Martin,et al.  Detection of apoptotic cells using immunohistochemistry. , 2014, Cold Spring Harbor protocols.

[218]  G. Shapiro,et al.  First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[219]  G. Salvesen,et al.  Regulated cell death: signaling and mechanisms. , 2014, Annual review of cell and developmental biology.

[220]  J. Infante,et al.  Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[221]  Brian J. Smith,et al.  Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity. , 2014, ACS medicinal chemistry letters.

[222]  W. Curran,et al.  Small Molecule Bax Agonists for Cancer Therapy , 2014, Nature Communications.

[223]  P. Opolon,et al.  Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer , 2014, Cell Death and Disease.

[224]  T. Bush,et al.  Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. , 2014, Cancer cell.

[225]  M. Loh,et al.  Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. , 2014, Cancer discovery.

[226]  J. Martinez-Climent,et al.  Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. , 2014, Blood.

[227]  H. Watari,et al.  Apoptosis and Molecular Targeting Therapy in Cancer , 2014, BioMed research international.

[228]  S. Ghosh,et al.  Regulation of NF-κB by TNF family cytokines. , 2014, Seminars in immunology.

[229]  A. Letai,et al.  Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. , 2014, Cancer research.

[230]  Y. Maejima,et al.  Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. , 2014, Molecular cell.

[231]  D. Green,et al.  Die another way – non-apoptotic mechanisms of cell death , 2014, Journal of Cell Science.

[232]  J. von Pawel,et al.  Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. , 2014, Clinical lung cancer.

[233]  S. Alkan,et al.  Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma. , 2014, Leukemia research.

[234]  Brian J. Smith,et al.  Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL. , 2014, ACS medicinal chemistry letters.

[235]  Steven P. Angus,et al.  Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer , 2014, Clinical Cancer Research.

[236]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[237]  L. Walensky,et al.  Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress , 2014, Journal of medicinal chemistry.

[238]  S. Chandarlapaty,et al.  Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. , 2014, Cancer discovery.

[239]  Matthew E. Welsch,et al.  Regulation of Ferroptotic Cancer Cell Death by GPX4 , 2014, Cell.

[240]  L. Desjardins,et al.  Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts , 2014, PloS one.

[241]  M. El-Bahrawy,et al.  Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1 , 2013, Cell Death and Differentiation.

[242]  Jeffrey W. Scott,et al.  Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors , 2014, Investigational New Drugs.

[243]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[244]  L. Saltz,et al.  TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer , 2013, Cancer.

[245]  Z. Wainberg,et al.  A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. , 2013, Clinical colorectal cancer.

[246]  D. Felsher,et al.  BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. , 2013, Blood.

[247]  Peter Sorger,et al.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. , 2013, Molecular cell.

[248]  Tao Zhang,et al.  A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[249]  W. Curran,et al.  Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. , 2013, Cancer research.

[250]  L. Vassilev,et al.  Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy , 2013, Proceedings of the National Academy of Sciences.

[251]  Jing Zhang,et al.  Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. , 2013, Journal of medicinal chemistry.

[252]  Brian J. Smith,et al.  Structure-guided design of a selective BCL-X(L) inhibitor. , 2013, Nature chemical biology.

[253]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[254]  Victoria Del Gaizo Moore,et al.  BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. , 2013, Cancer letters.

[255]  R. Preissner,et al.  Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode , 2013, Cell Death and Disease.

[256]  R. Ramlau,et al.  A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[257]  E. Messaris,et al.  Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.

[258]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[259]  J. Silke,et al.  Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. , 2013, Cold Spring Harbor perspectives in biology.

[260]  Travis J Cohoon,et al.  Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.

[261]  P. Fisher,et al.  Targeting the Bcl-2 family for cancer therapy , 2013, Expert opinion on therapeutic targets.

[262]  B. Widemann,et al.  Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[263]  Z. Duan,et al.  Interleukin-6 signaling pathway in targeted therapy for cancer. , 2012, Cancer treatment reviews.

[264]  B. R. Bowman,et al.  Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin , 2012, Proceedings of the National Academy of Sciences.

[265]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[266]  X. Jiang,et al.  Clearing the final hurdles to mitochondrial apoptosis: regulation post cytochrome C release. , 2012, Experimental oncology.

[267]  S. Malek,et al.  Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. , 2012, Bioorganic & medicinal chemistry letters.

[268]  K. Coombes,et al.  Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells , 2012, Annals of Hematology.

[269]  P. Dent,et al.  CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. , 2012, Cancer research.

[270]  L. Walensky,et al.  Direct and selective small-molecule activation of proapoptotic BAX. , 2012, Nature chemical biology.

[271]  Wei Gu,et al.  Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence , 2012, Cell.

[272]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[273]  H. Scher,et al.  Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors , 2012, Clinical Cancer Research.

[274]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[275]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[276]  Simone Fulda,et al.  Targeting IAP proteins for therapeutic intervention in cancer , 2012, Nature Reviews Drug Discovery.

[277]  Peter S. Kutchukian,et al.  Structure of the stapled p53 peptide bound to Mdm2. , 2012, Journal of the American Chemical Society.

[278]  M. Vogler,et al.  BCL2A1: the underdog in the BCL2 family , 2011, Cell Death and Differentiation.

[279]  J. Soria,et al.  Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[280]  H. Steller,et al.  Programmed Cell Death in Animal Development and Disease , 2011, Cell.

[281]  A. Eggermont,et al.  Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[282]  S. Digumarthy,et al.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. , 2011, Cancer discovery.

[283]  J. Martinou,et al.  Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. , 2011, Developmental cell.

[284]  M. Bickle,et al.  Characterization of peptide aptamers targeting Bfl-1 anti-apoptotic protein. , 2011, Biochemistry.

[285]  S. Morris,et al.  Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[286]  C. Maki,et al.  Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 , 2011, Oncogene.

[287]  Nico Tjandra,et al.  Bcl-xL Retrotranslocates Bax from the Mitochondria into the Cytosol , 2011, Cell.

[288]  Peter K. Sorger,et al.  Measuring and Modeling Apoptosis in Single Cells , 2011, Cell.

[289]  E. Ulukaya,et al.  Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients , 2011, Radiology and oncology.

[290]  Adam R. Johnson,et al.  Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 , 2011, Nature.

[291]  P. Oliver,et al.  Combined modality therapy with TRAIL or agonistic death receptor antibodies , 2011, Cancer biology & therapy.

[292]  L. Crawford,et al.  Proteasome inhibitors in cancer therapy , 2011, Journal of Cell Communication and Signaling.

[293]  S. Gygi,et al.  SCFFbw7 Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction , 2010, Nature.

[294]  R. Jemmerson,et al.  The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. , 2010, Molecular cell.

[295]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[296]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[297]  J. Vose,et al.  A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma , 2010, British Journal of Cancer.

[298]  R. Herbst,et al.  A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors , 2010, Clinical Cancer Research.

[299]  J. Roth,et al.  Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim , 2010, PloS one.

[300]  Wafik S El-Deiry,et al.  Current strategies to target p53 in cancer. , 2010, Biochemical pharmacology.

[301]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[302]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[303]  Emiko Fire,et al.  The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer , 2010, Nature chemical biology.

[304]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[305]  M. Prados,et al.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.

[306]  R. Preissner,et al.  Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma , 2010, The Journal of cell biology.

[307]  R. Herbst,et al.  A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies , 2010, Clinical Cancer Research.

[308]  H. Wakelee,et al.  Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[309]  V. Heinemann,et al.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer , 2010, British Journal of Cancer.

[310]  D. Newmeyer,et al.  Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. , 2009, Molecular biology of the cell.

[311]  Kwok-Kin Wong,et al.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.

[312]  Osamu Takeuchi,et al.  Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. , 2009, Molecular cell.

[313]  B. Korn,et al.  Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance in Gliomas , 2009, Clinical Cancer Research.

[314]  S. Sleijfer,et al.  Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study , 2009, Clinical Cancer Research.

[315]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[316]  V. Rangnekar,et al.  The Tumor Suppressor Par-4 Activates an Extrinsic Pathway for Apoptosis , 2009, Cell.

[317]  W. El-Deiry,et al.  Cell Death: A New Par-4 the TRAIL , 2009, Cell.

[318]  Jian Yu,et al.  PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells , 2009, Oncogene.

[319]  G. Gores,et al.  Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[320]  Christina Falschlehner,et al.  Following TRAIL’s path in the immune system , 2009, Immunology.

[321]  F. Balkwill.  Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[322]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[323]  G. Cohen,et al.  Bcl-2 inhibitors: small molecules with a big impact on cancer therapy , 2009, Cell Death and Differentiation.

[324]  Rakesh Kumar,et al.  AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. , 2009, Blood.

[325]  S. Fulda.  Tumor resistance to apoptosis , 2009, International journal of cancer.

[326]  J. Carrell,et al.  Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib , 2009, Molecular Cancer Therapeutics.

[327]  I. Morison,et al.  Targeting the Apoptosome for Cancer Therapy , 2009, Clinical Cancer Research.

[328]  Donald Wlodkowic,et al.  Flow cytometry-based apoptosis detection. , 2009, Methods in molecular biology.

[329]  Christina Falschlehner,et al.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. , 2009, Advances in experimental medicine and biology.

[330]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[331]  S. Lam,et al.  The xc− cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine , 2009, Cancer Chemotherapy and Pharmacology.

[332]  D. Andrews,et al.  Bid: a Bax-like BH3 protein , 2008, Oncogene.

[333]  T. Mak,et al.  Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK , 2008, Nature Immunology.

[334]  W. El-Deiry,et al.  Structural and Functional Basis for Therapeutic Modulation of p53 Signaling , 2008, Clinical Cancer Research.

[335]  S. Fulda,et al.  Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. , 2008, Cancer research.

[336]  P. Fisher,et al.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation , 2008, Cancer biology & therapy.

[337]  S. McClue,et al.  Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents , 2008, Clinical Cancer Research.

[338]  A. Oza,et al.  A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.

[339]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[340]  J. Lieberman,et al.  Death by a thousand cuts: granzyme pathways of programmed cell death. , 2008, Annual review of immunology.

[341]  E. Borden,et al.  Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL , 2008, Oncogene.

[342]  A. Klein-Szanto,et al.  TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. , 2008, The Journal of clinical investigation.

[343]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[344]  R. Stahel,et al.  Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin , 2007, Molecular Cancer.

[345]  R. Plummer,et al.  Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers , 2007, Clinical Cancer Research.

[346]  D. Tenen,et al.  BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations , 2007, PLoS medicine.

[347]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[348]  N. Müller,et al.  Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L , 2007, Cell Death and Differentiation.

[349]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[350]  Suzanne F. Jones,et al.  A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI , 2007 .

[351]  Nektarios Tavernarakis,et al.  Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1 , 2007, The EMBO journal.

[352]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[353]  M. Hidalgo,et al.  EGFR inhibitor-mediated apoptosis in solid tumors. , 2007, Journal of experimental therapeutics & oncology.

[354]  S. Goff.  Genetic Control of Programmed Cell Death in the Nematode Caenorhabditis elegans 1 , 2007 .

[355]  T. Cotter,et al.  Key apoptosis regulating proteins are down-regulated during postnatal tissue development. , 2007, The International journal of developmental biology.

[356]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[357]  D. Lindner,et al.  Nitrosylcobalamin Promotes Cell Death via S Nitrosylation of Apo2L/TRAIL Receptor DR4 , 2006, Molecular and Cellular Biology.

[358]  G. Salvesen,et al.  Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.

[359]  S. Ely,et al.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.

[360]  Sara Cipolat,et al.  OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion , 2006, Cell.

[361]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[362]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[363]  K. Imai,et al.  Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis , 2006, Cell Death and Differentiation.

[364]  E. Liu,et al.  Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[365]  C. Thiele,et al.  TrkA Induces Apoptosis of Neuroblastoma Cells and Does So via a p53-dependent Mechanism*[boxs] , 2005, Journal of Biological Chemistry.

[366]  W. El-Deiry,et al.  Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin , 2005, Cancer biology & therapy.

[367]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[368]  Wei Guo,et al.  Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. , 2005, Neoplasia.

[369]  R. Zeillinger,et al.  Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer , 2005, Molecular Cancer Research.

[370]  E. White,et al.  Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. , 2005, Cancer cell.

[371]  S. Lowe,et al.  DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis , 2005, Molecular and Cellular Biology.

[372]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[373]  W. El-Deiry,et al.  Overview of cell death signaling pathways , 2005, Cancer biology & therapy.

[374]  D. Kondziolka,et al.  Sensitivity to radiation-induced apoptosis and neuron loss declines rapidly in the postnatal mouse neocortex , 2005, International journal of radiation biology.

[375]  K. Das,et al.  Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. , 2005, The Biochemical journal.

[376]  S. Korsmeyer,et al.  Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.

[377]  W. El-Deiry,et al.  Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.

[378]  T. Inaba,et al.  Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors , 2004, Molecular and Cellular Biology.

[379]  David A Hildeman,et al.  ×Phosphorylation of Bax Ser184 by Akt Regulates Its Activity and Apoptosis in Neutrophils* , 2004, Journal of Biological Chemistry.

[380]  T. Taguchi,et al.  Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[381]  N. Niederle,et al.  Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease , 2004, Cancer Immunology, Immunotherapy.

[382]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.

[383]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[384]  M. Freeman,et al.  Mitochondrial membrane remodelling regulated by a conserved rhomboid protease , 2003, Nature.

[385]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[386]  E. Wagner,et al.  Activation of ERK1/2 by ΔRaf-1 : ER* represses Bim expression independently of the JNK or PI3K pathways , 2003, Oncogene.

[387]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[388]  B. Guiard,et al.  The ClpB Homolog Hsp78 Is Required for the Efficient Degradation of Proteins in the Mitochondrial Matrix* , 2002, The Journal of Biological Chemistry.

[389]  I. Gojo,et al.  The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[390]  Joanna K. Sax,et al.  BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.

[391]  Mason R. Mackey,et al.  Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane , 2002, Cell.

[392]  P. Vandenabeele,et al.  The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet , 2002, Cell Death and Differentiation.

[393]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[394]  C. Thompson,et al.  Pathways of Apoptosis in Lymphocyte Development, Homeostasis, and Disease , 2002, Cell.

[395]  J. Pinski,et al.  Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. , 2002, Cancer research.

[396]  Luca Scorrano,et al.  A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. , 2002, Developmental cell.

[397]  Wafik S El-Deiry,et al.  Defining characteristics of Types I and II apoptotic cells in response to TRAIL. , 2002, Neoplasia.

[398]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[399]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[400]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[401]  Howard Y. Chang,et al.  Proteases for Cell Suicide: Functions and Regulation of Caspases , 2000, Microbiology and Molecular Biology Reviews.

[402]  J. Tschopp,et al.  The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation* , 2000, The Journal of Biological Chemistry.

[403]  A. Saraste,et al.  Morphologic and biochemical hallmarks of apoptosis. , 2000, Cardiovascular research.

[404]  H. Hibshoosh,et al.  Induction of autophagy and inhibition of tumorigenesis by beclin 1 , 1999, Nature.

[405]  S. R. Datta,et al.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.

[406]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[407]  S. Korsmeyer,et al.  Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis , 1999, Nature.

[408]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[409]  R. Davis,et al.  Imaging of apoptosis (programmed cell death) with 99mTc annexin V. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[410]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[411]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[412]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[413]  J. Mangion,et al.  BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability , 1998, Oncogene.

[414]  A. Strasser,et al.  Bim: a novel member of the Bcl‐2 family that promotes apoptosis , 1998, The EMBO journal.

[415]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[416]  L. Hood,et al.  Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. , 1997, Immunity.

[417]  J. Tschopp,et al.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.

[418]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[419]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[420]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[421]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[422]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[423]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[424]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[425]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[426]  Manuel C. Peitsch,et al.  Characterization of Fas (Apo-1, CD95)-Fas Ligand Interaction* , 1997, The Journal of Biological Chemistry.

[427]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[428]  R. Weichselbaum,et al.  Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[429]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[430]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[431]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[432]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[433]  Stephen W. Fesik,et al.  NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain , 1996, Nature.

[434]  C. Milliman,et al.  BID: a novel BH3 domain-only death agonist. , 1996, Genes & development.

[435]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[436]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[437]  John Calvin Reed,et al.  Proapoptotic Protein Bax Heterodimerizes with Bcl-2 and Homodimerizes with Bax via a Novel Domain (BH3) Distinct from BH1 and BH2 (*) , 1996, The Journal of Biological Chemistry.

[438]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[439]  T. Taguchi,et al.  [Phase I study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[440]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[441]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[442]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[443]  Y. Lazebnik,et al.  Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.

[444]  Z. Oltvai,et al.  Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. , 1993, Seminars in cancer biology.

[445]  N. Davidson,et al.  Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. , 1993, Cancer research.

[446]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[447]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[448]  L. Truong,et al.  Immunohistochemical localization of granzyme B antigen in cytotoxic cells in human tissues. , 1991, The American journal of pathology.

[449]  H. Horvitz,et al.  Mechanisms and functions of cell death. , 1991, Annual review of cell biology.

[450]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[451]  H. Varmus.  Retroviruses and Oncogenes I , 1990 .

[452]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[453]  H. Varmus.  Nobel lecture. Retroviruses and oncogenes. I. , 1990, Bioscience reports.

[454]  A. Dalgleish.  Retroviruses and oncogenes. , 1989, British journal of rheumatology.

[455]  H. Kuriyama,et al.  Toxic effect of tumor necrosis factor on tumor vasculature in mice. , 1988, Cancer research.

[456]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[457]  K. Latham,et al.  Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. , 1987, Journal of immunology.

[458]  H. Horvitz,et al.  Genetic control of programmed cell death in the nematode C. elegans , 1986, Cell.

[459]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[460]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[461]  A. Wyllie.  Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation , 1980, Nature.